Investors

AddLife shares are traded on Nasdaq Stockholm, Nordic Large Cap

ADD Lonsamhet Vit

The share

Chart Bar

Financial reports and presentations

Calendar

Humans

Corporate governance

  • Organic growth and stable margin

    Continued organic growth and stable margin in the third quarter - a quarter that is normally somewhat weaker seasonally. The work on profitability improvements is progressing according to plan. 

    comments by the ceo
    1 Fredrik Dalborg Q3 2024

Listen to our latest presentation

 

AddLife creates value

The laboratory and medical technology market is relatively insensitive to economic fluctuations. Growth tends to be stable and is mainly driven by population growth and an ageing population. These trends increase the demand for AddLife's healthcare and research products. Historically, the markets where we operate have grown at an annual rate of 2-4 percent.

AddLife’s subsidiaries are strongly cash generative, which gives financial opportunity for acquisitions and investments.

ADD Lonsamhet Vit

AddLife has substantial experience of acquisitions, identifying candidates and completing successful transactions.

ADD Ansvar Vit

AddLife’s subsidiaries have strong sales organisations with high technological expertise and long term customer relationships.

ADD Engagemang Vit

Target fulfilment 2023

Earnings growth

Profitability

Dividend

Contact us!

The investor pages contain all published financial information to facilitate investment decisions.

We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information, or if you have any suggestions for improving our service.

Contact: ir@add.life

IR- and press contacts

Fredrik Dalborg (2)

Fredrik Dalborg

CEO

fredrik.dalborg@add.life

Christina Rubenhag

Christina Rubenhag

CFO

christina.rubenhag@add.life

Julie Oleary

Julie O'Leary

Investor Relations Manager

julie.oleary@add.life

Subscribe